Title:
PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING MALIGNANT BREAST CANCER
Document Type and Number:
WIPO Patent Application WO/2022/164269
Kind Code:
A1
Abstract:
The present invention relates to a pharmaceutical composition for treating or preventing malignant breast cancer and, more particularly, to a composition for transdifferentiation of ER-negative breast cancer to luminal breast cancer, comprising an HDAC1/2 inhibitor and a BCL11A inhibitor as active ingredients, and use of the composition. According to the present invention, when target genes of the present invention are inhibited, BLT is induced so that basal-like or triplet-negative breast cancer is transdifferentiated to luminal A subtype breast cancer which is responsive to anticancer therapy, that is, being curable by hormone therapy. Accordingly, an effective and novel drug treatment that has not been conventionally attempted may be provided, thereby not only increasing the survival rate of patients through targeted therapy by realizing personalized medicine, but also contributing to an improvement in the quality of life that results from unnecessary anticancer drug therapy.
More Like This:
Inventors:
CHO KWANG HYUN (KR)
CHOI SEA ROM (KR)
HWANG CHAE YOUNG (KR)
LEE JONG HOON (KR)
CHOI SEA ROM (KR)
HWANG CHAE YOUNG (KR)
LEE JONG HOON (KR)
Application Number:
PCT/KR2022/001622
Publication Date:
August 04, 2022
Filing Date:
January 28, 2022
Export Citation:
Assignee:
KOREA ADVANCED INST SCI & TECH (KR)
International Classes:
A61K48/00; A23L33/13; A23L33/18; A61K31/138; A61K31/7105; A61K38/15; A61K45/06; A61P35/00
Domestic Patent References:
| WO2017081171A1 | 2017-05-18 |
Foreign References:
| US20170298360A1 | 2017-10-19 |
Other References:
FAN MINMIN, CHEN JINGWEI, GAO JIAN, XUE WENWEN, WANG YIXUAN, LI WUHAO, ZHOU LIN, LI XIN, JIANG CHENGFEI, SUN YANG, WU XUEFENG, WU : "Triggering a switch from basal- to luminal-like breast cancer subtype by the small-molecule diptoindonesin G via induction of GABARAPL1", CELL DEATH & DISEASE, vol. 11, no. 8, 1 August 2020 (2020-08-01), pages 1 - 13, XP055954006, DOI: 10.1038/s41419-020-02878-z
HUA ZHAO , YEHENEW M AGAZIE: "Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment", BMC CANCER, vol. 15, no. 1, 1 January 2015 (2015-01-01), LONDON, GB , pages 1 - 12, XP021219175, ISSN: 1471-2407, DOI: 10.1186/s12885-015-1131-2
CYR A R; KULAK M V; PARK J M; BOGACHEK M V; SPANHEIMER P M; WOODFIELD G W; WHITE-BAER L S; O'MALLEY Y Q; SUGG S L; OLIVIER A K; ZH: "TFAP2C governs the luminal epithelial phenotype in mammary development and carcinogenesis", ONCOGENE, vol. 34, no. 4, 1 January 2015 (2015-01-01), London , pages 436 - 444, XP036973157, ISSN: 0950-9232, DOI: 10.1038/onc.2013.569
CHOI SEA R., HWANG CHAE YOUNG, LEE JONGHOON, CHO KWANG-HYUN: "Network Analysis Identifies Regulators of Basal-Like Breast Cancer Reprogramming and Endocrine Therapy Vulnerability", CANCER RESEARCH, vol. 82, no. 2, 15 January 2022 (2022-01-15), US , pages 320 - 333, XP055954017, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-21-0621
"Remington's Pharmaceutical Science", MACK PUBLISHING COMPANY
HUA ZHAO , YEHENEW M AGAZIE: "Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment", BMC CANCER, vol. 15, no. 1, 1 January 2015 (2015-01-01), LONDON, GB , pages 1 - 12, XP021219175, ISSN: 1471-2407, DOI: 10.1186/s12885-015-1131-2
CYR A R; KULAK M V; PARK J M; BOGACHEK M V; SPANHEIMER P M; WOODFIELD G W; WHITE-BAER L S; O'MALLEY Y Q; SUGG S L; OLIVIER A K; ZH: "TFAP2C governs the luminal epithelial phenotype in mammary development and carcinogenesis", ONCOGENE, vol. 34, no. 4, 1 January 2015 (2015-01-01), London , pages 436 - 444, XP036973157, ISSN: 0950-9232, DOI: 10.1038/onc.2013.569
CHOI SEA R., HWANG CHAE YOUNG, LEE JONGHOON, CHO KWANG-HYUN: "Network Analysis Identifies Regulators of Basal-Like Breast Cancer Reprogramming and Endocrine Therapy Vulnerability", CANCER RESEARCH, vol. 82, no. 2, 15 January 2022 (2022-01-15), US , pages 320 - 333, XP055954017, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-21-0621
"Remington's Pharmaceutical Science", MACK PUBLISHING COMPANY
Attorney, Agent or Firm:
KIM, Soon Woong (KR)
Download PDF: